Karyopharm Therapeutics Stock Price, News & Analysis (NASDAQ:KPTI) $0.86 +0.02 (+2.38%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.84▼$0.8850-Day Range$0.68▼$1.3452-Week Range$0.67▼$4.87Volume731,389 shsAverage Volume2.28 million shsMarket Capitalization$98.50 millionP/E RatioN/ADividend YieldN/APrice Target$5.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Karyopharm Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside581.1% Upside$5.86 Price TargetShort InterestBearish16.49% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment-0.92Based on 2 Articles This WeekInsider TradingAcquiring Shares$50,191 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.13) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector509th out of 954 stocksBiotechnology Industry52nd out of 109 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.86, Karyopharm Therapeutics has a forecasted upside of 581.1% from its current price of $0.86.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.49% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 1.2 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of -0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have bought 367.46% more of their company's stock than they have sold. Specifically, they have bought $50,191.00 in company stock and sold $10,737.00 in company stock.Percentage Held by InsidersOnly 3.32% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions70.47% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.13) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Karyopharm Therapeutics Stock (NASDAQ:KPTI)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPTI Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comGreat week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous yearNovember 29, 2023 | seekingalpha.comKaryopharm Therapeutics; Promising Potential With 3 Ongoing Phase 3 Studies But RiskyDecember 8, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.November 16, 2023 | bizjournals.comThe Petri Dish: Concerns mar Verve data; Alnylam-Roche drug shows promiseNovember 6, 2023 | markets.businessinsider.comHold Rating on Karyopharm Therapeutics: Evaluating Q3 Results, Impact of PAP and Prospects of Xpovio in Myelofibrosis TreatmentNovember 6, 2023 | markets.businessinsider.comKaryopharm : Data In Selinexor-Treated Patients With Endometrial Cancer Shows Improvements In PFSNovember 6, 2023 | msn.comKaryopharm reports encouraging data for endometrial cancer drug candidateNovember 6, 2023 | finance.yahoo.comKaryopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyDecember 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | markets.businessinsider.comBuy Rating Recommended for Karyopharm Therapeutics Amid Strong 3Q Results and Promising Xpovio SalesNovember 3, 2023 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | msn.comKaryopharm Therapeutics GAAP EPS of -$0.30 misses by $0.05, revenue of $36M misses by $1.4MNovember 2, 2023 | finance.yahoo.comKaryopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)November 2, 2023 | finance.yahoo.comKaryopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 MillionNovember 2, 2023 | finance.yahoo.comKaryopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNovember 2, 2023 | msn.comKaryopharm Therapeutics Q3 2023 Earnings PreviewNovember 1, 2023 | markets.businessinsider.comHere's what Wall Street expects from Karyopharm Therapeutics's earnings reportOctober 30, 2023 | msn.comKaryopharm, Bristol Myers to evaluate drug combination for treatment of multiple myelomaOctober 26, 2023 | finance.yahoo.comKaryopharm to Report Third Quarter 2023 Financial Results on November 2, 2023October 17, 2023 | fool.comKaryopharm Therapeutics (NASDAQ: KPTI)September 29, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Karyopharm Therapeutics (KPTI), Pliant Therapeutics (PLRX)September 26, 2023 | finance.yahoo.comKaryopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual MeetingsSeptember 1, 2023 | finance.yahoo.comKaryopharm Appoints Zhen Su, MD, MBA to its Board of DirectorsAugust 21, 2023 | msn.comKaryopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far AwayAugust 4, 2023 | msn.comPiper Sandler Maintains Karyopharm Therapeutics (KPTI) Overweight RecommendationAugust 3, 2023 | benzinga.com6 Analysts Have This to Say About Karyopharm TherapeuticsAugust 3, 2023 | finance.yahoo.comDozens more biotech jobs axed as two firms make cutsSee More Headlines Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees385Year FoundedN/APrice Target and Rating Average Stock Price Target$5.86 High Stock Price Target$10.00 Low Stock Price Target$3.00 Potential Upside/Downside+579.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,290,000.00 Net Margins-95.82% Pretax Margin-95.64% Return on EquityN/A Return on Assets-44.66% Debt Debt-to-Equity RatioN/A Current Ratio4.24 Quick Ratio4.19 Sales & Book Value Annual Sales$145.87 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-5.75Miscellaneous Outstanding Shares114,534,000Free Float110,731,000Market Cap$98.72 million OptionableOptionable Beta-0.18 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 56)President, CEO & Director Comp: $1.36MDr. Sharon Shacham M.B.A. (Age 53)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Comp: $1.4MMr. Michael P. Mason CPA (Age 48)M.B.A., Executive VP, CFO & Treasurer Comp: $681.59kMr. Michael J. Mano J.D. (Age 46)Senior VP, General Counsel & Secretary Comp: $625.08kMs. Sohanya Cheng M.B.A. (Age 40)Executive VP & Chief Commercial Officer Comp: $664.3kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Mansoor Raza Mirza M.D. (Age 62)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Comp: $150kMr. Cameron Peters (Age 63)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. James Accumanno J.D.Chief Compliance OfficerMore ExecutivesKey CompetitorsEton PharmaceuticalsNASDAQ:ETONZyVersa TherapeuticsNASDAQ:ZVSACytomX TherapeuticsNASDAQ:CTMXAtossa TherapeuticsNASDAQ:ATOSG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInsiders & InstitutionsRichard A PaulsonSold 3,622 sharesTotal: $2,861.38 ($0.79/share)Deutsche Bank AGSold 1,534,953 shares on 11/24/2023Ownership: 0.051%Graham Capital Management L.P.Bought 19,895 shares on 11/22/2023Ownership: 0.072%Jacobs Levy Equity Management Inc.Bought 1,676,673 shares on 11/17/2023Ownership: 2.055%Tejara Capital LtdSold 66,603 shares on 11/15/2023Ownership: 0.941%View All Insider TransactionsView All Institutional Transactions KPTI Stock Analysis - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price target for 2024? 6 brokers have issued 1-year target prices for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they predict the company's stock price to reach $5.86 in the next year. This suggests a possible upside of 581.1% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2023? Karyopharm Therapeutics' stock was trading at $3.40 on January 1st, 2023. Since then, KPTI shares have decreased by 74.7% and is now trading at $0.86. View the best growth stocks for 2023 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The firm earned $36.01 million during the quarter, compared to analyst estimates of $37.34 million. What ETF holds Karyopharm Therapeutics' stock ? iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (7.25%), Jacobs Levy Equity Management Inc. (2.05%), Barclays PLC (1.01%), Tejara Capital Ltd (0.94%), Tejara Capital Ltd (0.94%) and Northern Trust Corp (0.86%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KPTI) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.